Evidence map›Paper›PMID 40673161›Full record

ArticleMolecular therapy. Nucleic acids2025

Sequence simplification of antigen coding IVT mRNA allows accelerated synthetic DNA template generation and epitope immunogenicity validation.

Arthur Esprit, Dorien Autaers, Ilke Aernout, Ine Lentacker, Steve Pascolo, Kris Thielemans, Karine Breckpot, Lorenzo Franceschini

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Minimalist mRNAs: A fast track to cancer vaccines.Molecular therapy. Nucleic acids · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arthur EspritTranslational Oncology Research Centre, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Dorien AutaersTranslational Oncology Research Centre, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Ilke AernoutGhent Research Group on Nanomedicines, Faculty of Pharmacy, Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.
Ine LentackerGhent Research Group on Nanomedicines, Faculty of Pharmacy, Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.
Steve PascoloDepartment of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Kris ThielemansTranslational Oncology Research Centre, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Karine BreckpotTranslational Oncology Research Centre, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Lorenzo FranceschiniTranslational Oncology Research Centre, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent surge in therapeutic mRNA for vaccination has provided a blueprint for the design of the mRNA molecule, as several complex structural elements indicated as 5' and 3' untranslated regions (UTRs) and poly-A tail have been identified as necessary for

Indexed as

cancerelectroporationIVT-mRNAlipid nanoparticlesMT: Oligonucleotides: Therapies and Applicationsneoepitopevaccination

Identifiers

PMID40673161
PMCPMC12266495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.